-
Quantitative flow ratio versus fractional flow reserve: 2-year follow-up of the FAVOR III Europe trial
CONCLUSIONS: The excess risks associated with QFR-guided revascularisation compared with FFR were confined to the first year. From 1 to 2 years, the rates of MACE developed similarly in the QFR and the FFR groups. →
-
Effects of Daily Saskatoon Berry Supplementation on Cardiometabolic Health, Gut Microbiota, and Short-Chain Fatty Acids in Healthy Adults
Saskatoon berry (SB), a traditional food of Indigenous people, has been associated with cardiometabolic benefits in animal models; however, its effects on humans remain unclear. This study investigated the effects of dried SB consumption on cardiometabolic outcomes, gut microbiota, and short-chain fatty acids (SCFAs) profiles in healthy adults. In a 10-week, single-arm, and open-label trial,… →
-
Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial
BACKGROUND: Second generation tyrosine kinase inhibitors (TKIs) have improved response rates in patients with chronic phase chronic myeloid leukaemia (CP-CML). Phase 2 trials demonstrated increased deep molecular response rates when combining second generation TKIs with pegylated interferon alfa (Peg-IFN). This trial aimed to evaluate the efficacy and the safety of combining nilotinib with Peg-IFN alfa-2a… →
-
Lactiplantibacillus plantarum Z6 Improves Functional Constipation in Infants
CONCLUSIONS: L. plantarum Z6 is a safe and effective probiotic intervention for infantile functional constipation. The results highlight its potential to improve bowel function and beneficially reshape the gut microbiota, offering a microbiota-targeted therapeutic strategy for pediatric gastrointestinal disorders. Chinese Clinical Trial Registry ID: ChiCTR2300073079. →
-
Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial
BACKGROUND: People living with HIV have an increased risk of cardiovascular disease, but data on the development and consequences of hypertension remain limited. Using data from REPRIEVE, a global randomised trial of pitavastatin for primary cardiovascular prevention among people with HIV, we evaluated whether pitavastatin reduces the incidence of hypertension among participants without hypertension at… →
-
What Happens When AI Transforms a Specialized Field Overnight?
Before AI came for your job, it came for the biologists’. In 2020, Google DeepMind researchers unveiled AlphaFold2, an AI model that tackled a major scientific challenge: Is it possible to determine a protein’s structure from its ingredients alone? The ability to do so without slow and expensive lab experiments carried the potential to revolutionize… →
-
With Status Symbols, Let Someone Else Do the Bragging
Over a century ago, the economist Thorstein Veblen popularized the age-old idea that by purchasing luxury goods, and displaying them, people can communicate their elevated reputation—such as their wealth, success, or competence. This practice, which he referred to as “conspicuous consumption,” has been going on for millennia. Studies of Neolithic societies, for example, show evidence… →
-
Swipe or Tap? How Age Shapes the Adoption of New Technologies
In Europe, over a fifth of the population is at least 65 years old. In Japan, the figure is nearly 30 percent. And the World Health Organization projects the percentage of people across the globe who are over 60 years old will reach 22 percent by 2050, just about double what it was in 2015. … →
-
Deconstructing Cursor’s Growth Playbook: $4M to $2B ARR in 18 Months
This is Part IV of the Deconstructing GTM series. If you missed the previous editions, you can catch up on them here: Read Part I (ClickUp), Part II (Vanta at $100M), and Part III (Gamma at $100M). Slack took two and a half years to reach $100M ARR. Dropbox took four years. Cursor took twelve… →
-
Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results
CONCLUSION: Valoctocogene roxaparvovec provides durable hemostatic efficacy, FVIII activity, and improved health-related quality of life for ≥5 years, with no new safety signals. →
